Multiply Labs

• 2026-10-06 - Series B - $75M - Multiply Labs raises $75M Series B for robotic drug manufacturing

  Multiply Labs completed a NantWorks-led Series B to advance robotic manufacturing of gene therapies, mRNA and other complex medicines. - source: multiplylabs.com

• 2021-04-14 - Series A - $20M - Multiply Labs raises $20M Series A for robotic drug production

  Multiply Labs completed a Casdin Capital-led Series A supporting automated manufacturing of individualized medicines. - source: biospace.com

• Casdin Capital - Lead - VC - 2 funding events - repeat backer - first seen 2021-04-14 - latest 2026-10-06
• Fifty Years - Participant - Angel / Individual - 2 funding events - repeat backer - first seen 2021-04-14 - latest 2026-10-06
• Lux Capital - Participant - VC - 2 funding events - repeat backer - first seen 2021-04-14 - latest 2026-10-06
• AstraZeneca - Participant - Unknown - 1 funding event - first seen 2026-10-06
• Founders Fund - Participant - VC - 1 funding event - first seen 2026-10-06
• Garage Capital - Participant - VC - 1 funding event - first seen 2021-04-14
• Lingotto - Participant - Unknown - 1 funding event - first seen 2026-10-06
• NantWorks - Lead - Unknown - 1 funding event - first seen 2026-10-06
• Ora Global - Participant - VC - 1 funding event - first seen 2026-10-06
• Pathfinder - Participant - Unknown - 1 funding event - first seen 2021-04-14
• Strange Ventures - Participant - VC - 1 funding event - first seen 2026-10-06
• Teradyne - Participant - Unknown - 1 funding event - first seen 2026-10-06

• Enrico Antonio Racca - Chief Supply Chain and Manufacturing Officer; Founding General Manager, Multiply Labs Italia - Leads robotic-cluster manufacturing, supply-chain development and regulated-production quality systems, and is establishing the company’s Italian manufacturing operation in Turin.
• Alice Melocchi - Co-founder and Chief Scientific Officer
• Fred Parietti - Co-founder and Chief Executive Officer

Events

• 2026-10-06 - Funding - Multiply Labs raises $75M Series B for robotic drug manufacturing

  AstraZeneca, Lux Capital and Founders Fund participated in the round. The financing brings cumulative funding since the company’s 2016 founding to more than $100 million. Customers operate the machines at their own facilities and purchase cartridges and technical support.

  Source
• 2026-05-27 - Org Change - Multiply Labs establishes Italian manufacturing subsidiary in Turin

  Enrico Antonio Racca, former Ferrari head of supply chain and manufacturing, became founding general manager and the parent company’s supply-chain and manufacturing chief. The Turin team is being built to recruit manufacturing staff, design a scalable supply chain and establish quality systems for regulated pharmaceutical environments.

  Source
• 2026-01-27 - Partnership - Multiply Labs reaches AstraZeneca agreement on GMP-ready production systems

  Four arms operate in parallel across instruments already used in cell-therapy manufacturing. The evaluation targets greater throughput in existing facilities while limiting process changes and maintaining clinical and commercial quality requirements.

  Source
• 2026-01-12 - Capability - Multiply Labs adopts NVIDIA robotics tools for biomanufacturing development

  Isaac Sim supports hardware simulation and software validation before changes reach physical systems. FoundationPose and FoundationStereo support learning from expert demonstrations, while GR00T work targets manipulation research.

  Source
• 2025-09-30 - Partnership - Multiply Labs expands Thermo Fisher collaboration to DynaCellect cell processing

  DynaCellect handles closed-system cell isolation, activation and bead removal in cell-therapy development and manufacturing. The collaboration extends earlier automation work with Heracell VIOS incubators and the Gibco CTS Rotea cell-processing system.

  Source
• 2025-06-12 - Partnership - Multiply Labs partners with Kyverna to evaluate robotic cell-therapy manufacturing

  KYV-102 combines a fully human CD19 CAR-T approach with Kyverna’s whole-blood rapid manufacturing process. Multiply Labs plans to use its Resonance pipeline to learn workflows from video demonstrations through automatic segmentation and trajectory extraction.

  Source
• 2024-09-24 - Partnership - Multiply Labs agrees Legend Biotech priority access to cell-therapy robotics

  The modular clusters use robotic arms to move materials between instruments already used in cell-therapy production. The approach targets adoption of automation while retaining established manufacturing processes. Legend co-developed the CAR-T treatment Carvykti with Johnson & Johnson, extending Multiply Labs’ work to a commercial cell-therapy developer.

  Source
• 2024-04-23 - Partnership - Multiply Labs plans robotic cell-therapy collaboration with Stanford LCGM

  Cell-therapy organizations will be able to compare manual processes with automated versions side by side. The robots are designed to use existing GMP instruments, consumables and reagents without major process changes. A Cytotherapy study provides the template, comparing manual and robotic cell expansion with the same equipment and materials.

  Source
• 2022-12-01 - Partnership - Multiply Labs deploys personalized-drug robotics with WuXi STA

  The system makes personalized-strength and multi-compartment capsules combining multiple active ingredients. It handles powders, blends, granules, beads and minitabs for pediatric, geriatric and rare-disease applications. The collaboration addresses conventional manufacturing that is restricted to one large batch at a time.

  Source
• 2021-04-14 - Funding - Multiply Labs raises $20M Series A for robotic drug production

  Lux Capital and Pathfinder, Founders Fund’s early-stage investment vehicle, joined seed investors Fifty Years and Garage Capital. Cumulative funding exceeded $25 million after the round. The financing supported cloud-controlled robotic systems for industrial-scale production.

  Source

Relationships

• AstraZeneca

  Technology Partner - Multiply Labs and AstraZeneca agreed to evaluate GMP-ready robotic systems for commercial-scale cell-therapy manufacturing.

Comparable profiles

• Hudson Lab Automation

  comparable profile - Lab Robotics Systems

• Robot on Rails

  comparable profile - Lab Robotics Systems

• Automata

  stack adjacency - Lab Instrument Orchestration

• Telescope Innovations

  stack adjacency - Lab Instrument Orchestration

• Infera

  stack adjacency - Lab Instrument Orchestration

• Epistra

  stack adjacency - Lab Instrument Orchestration

Shared workflows

• Overture Life

  workflow adjacency - Automated Lab Workcell

• Chemspeed Technologies

  workflow adjacency - Automated Lab Workcell

• Zeon Systems

  workflow adjacency - Automated Lab Workcell

Context tags

• Automated lab workcell - Workflow - https://www.multiplylabs.com/press/wuxista-2022 — Deployed instrument-operating robotic manufacturing system handles personalized solid oral formulations.
• Lab robotics systems - Peer Group - https://www.multiplylabs.com/ — Modular robot-arm clusters execute cell-therapy and pharmaceutical manufacturing workflows; company builds the system, not a humanoid arm.
• Lab instrument orchestration - Capability - https://www.multiplylabs.com/press/thermo-dynacellect-2025 — Integration with DynaCellect and prior Rotea/incubator workflows establishes instrument coordination.
• Lab automation sites - Customer Environment - https://www.multiplylabs.com/press/kyverna-2025 — Cell-therapy manufacturer evaluation is customer environment, not another peer identity.